Qube Research & Technologies LTD Janux Therapeutics, Inc. Transaction History

Qube Research & Technologies LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$35.12 - $64.78 $352,394 - $650,002	10,034 New	10,034 $420,000
Q3 2023 Nov 13, 2023	SELL	$9.56 - $14.0 $37,341 - $54,684	-3,906 Reduced 30.9%	8,735 $88,000
Q2 2023 Aug 14, 2023	BUY	$11.08 - $15.92 $140,062 - $201,244	12,641 New	12,641 $150,000
Q3 2021 Nov 12, 2021	SELL	$20.7 - $34.69 $296,196 - $496,379	-14,309 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$18.58 - $25.37 $265,861 - $363,019	14,309 New	14,309 $357,000

166

37.6M

85.3K

654K

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $2B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.